Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

PRALUENT DIN 02453835

Status: Marketed
Holder: SANOFI-AVENTIS CANADA INC
Molecule: ALIROCUMAB
Available to quote

Health Canada record

Active ingredient(s)ALIROCUMAB 150 MG
Dosage formSolution
RouteSubcutaneous
SchedulePRESCRIPTION; SCHEDULE D
ClassHuman
ATCC10AX14 ALIROCUMAB
Original market date29-Apr-2016
Current status date29-Apr-2016
SourceHealth Canada DPD

Establishment licence of the holder

sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing ALIROCUMAB

DINProductCompanyFormStrengthStatus
02453819PRALUENTSANOFI-AVENTIS CANADA INCSolutionALIROCUMAB 75 MGMarketed
02547732PRALUENTSANOFI-AVENTIS CANADA INCSolutionALIROCUMAB 300 MGMarketed
02453754PRALUENTSANOFI-AVENTIS CANADA INCSolutionALIROCUMAB 75 MGCancelled Post Market
02453762PRALUENTSANOFI-AVENTIS CANADA INCSolutionALIROCUMAB 150 MGCancelled Post Market

Notices of Compliance

NOCDateSubmissionReason
179762016-04-11New Drug Submission (NDS)
Request a quote for PRALUENT

How to read a Canadian DIN record